About: EMA401

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

EMA401 is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pain EMA401 has shown efficacy in preclinical models of shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT2R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. EMA401 target angiotensin II type 2 receptors, which may have importance for painful sensitisation.

Property	Value
dbo:abstract	EMA401 is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pain EMA401 has shown efficacy in preclinical models of shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT2R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. EMA401 target angiotensin II type 2 receptors, which may have importance for painful sensitisation. (en)
dbo:bioavailability	33.000000 (xsd:float)
dbo:casNumber	1316755-17-5
dbo:chEBI	150942
dbo:chEMBL	34124
dbo:fdaUniiCode	P9EW7EP34P
dbo:pubchem	9937291
dbo:thumbnail	wiki-commons:Special:FilePath/EMA401.svg?width=300
dbo:wikiPageExternalLink	https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx%3Fid=347597
dbo:wikiPageID	42433109 (xsd:integer)
dbo:wikiPageLength	15873 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1097364695 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Receptor_antagonists dbr:Competitive_inhibition dbr:Neuropathic_pain dbr:Angiotensin_II dbr:Postherpetic_neuralgia dbc:Drugs_acting_on_the_nervous_system dbr:Angiotensin dbr:Central_nervous_system
dbp:bioavailability	33.0
dbp:boilingPoint	745.300000 (xsd:double)
dbp:c	32 (xsd:integer)
dbp:casNumber	1316755 (xsd:integer)
dbp:chebi	150942 (xsd:integer)
dbp:chembl	34124 (xsd:integer)
dbp:chemspiderid	8068121 (xsd:integer)
dbp:density	1.256000 (xsd:double)
dbp:eliminationHalfLife	-43200.0
dbp:h	29 (xsd:integer)
dbp:image	EMA401 3D.jpg (en)
dbp:iupacName	-2 (xsd:integer)
dbp:legalStatus	Phase II Clinical Trials (en)
dbp:n	1 (xsd:integer)
dbp:o	5 (xsd:integer)
dbp:proteinBound	Angiotensin II Subtype 2 Receptor (en)
dbp:pubchem	9937291 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	COC1=COCC5=CC=CC=C5 (en)
dbp:solubility	14 (xsd:integer)
dbp:specificRotation	+ (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	GHBCIXGRCZIPNQ-UHFFFAOYSA-N (en)
dbp:unii	P9EW7EP34P (en)
dbp:wikiPageUsesTemplate	dbt:COI dbt:Infobox_drug dbt:Reflist dbt:Sub dbt:Fdacite
dcterms:subject	dbc:Receptor_antagonists dbc:Drugs_acting_on_the_nervous_system
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090
rdfs:comment	EMA401 is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pain EMA401 has shown efficacy in preclinical models of shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT2R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. EMA401 target angiotensin II type 2 receptors, which may have importance for painful sensitisation. (en)
rdfs:label	EMA401 (en)
owl:sameAs	freebase:EMA401 yago-res:EMA401 wikidata:EMA401 https://global.dbpedia.org/id/n5Q3
prov:wasDerivedFrom	wikipedia-en:EMA401?oldid=1097364695&ns=0
foaf:depiction	wiki-commons:Special:FilePath/EMA401.svg wiki-commons:Special:FilePath/EMA401_3D.jpg
foaf:isPrimaryTopicOf	wikipedia-en:EMA401
is dbo:wikiPageWikiLink of	dbr:Maree_Smith
is foaf:primaryTopic of	wikipedia-en:EMA401